anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The recommended adult dose for most patients is one (1) AMRIX 15 mg capsule taken once daily. Some patients may require up to 30 mg/day, given as one (1) AMRIX 30 mg capsule taken once daily or as two (2) AMRIX 15 mg capsules taken once daily.

It is recommended that doses be taken at approximately the same time each day.

Use of AMRIX for periods longer than two or three weeks is not recommended (see INDICATIONS AND USAGE).

Dosage Considerations for Special Patient Populations: AMRIX should not be used in the elderly or in patients with impaired hepatic function. (see WARNINGS)
NEW MATERIAL:A compound shown by the formulaI(A is a group shown by the formula II when R is H, a group shown by the formula III when R is OH, and a group shown by the formula IV when R is a group constituting 11,14- epoxy group; Q is a group constituting 11,14-epoxy). EXAMPLE:12,13-Deepoxy-13-hydroxymycinamicinI. USE:An oral or injection remedy for infectious deseases caused by Gram-positive bacteria or mycoplasm or an animal growth promotor. PROCESS:(A) Mycinamicin(MMN)Ior MMN II is reacted with an electron donor metal (e.g., zinc powder, etc.) and an ammonium salt (e.g., NH4Cl, etc.) in a hydrous polar solvent (e.g., water/tetrahydrofuran, etc.) or (B) a culture of a bacterium (e.g., Streptomyces variabilis TYJ-689, etc.) capable of converting MMNIor MMN II to the desired substance, its mold, or treated materials thereof are reacted with MMNIor MMN II in an aqueous medium in the absence of O2, to give a compound shown by the formulaI.
The invention provides a Chinese medicine formula for growing hair, which is characterized by comprising the following Chinese medicine components: 2 to 4 semen torreyae, 1 to 3 walnuts, 25 to 35 grams of Chinese arborvitae twig and 25 to 35 grams of yerbadetajo herba ecliptae. The preparation method of the formula comprises: washing the 2 to 4 semen torreyae, 1 to 3 walnuts, 25 to 35 grams of Chinese arborvitae twig and 25 to 35 grams of yerbadetajo herba ecliptae, which are the Chinese medicine materials, drying, and grinding into powder; and soaking the powder in wine for one week for later use. The using method of the formula comprises: applying the medicinal wine on head, massaging, impregnating a comb with the medicinal wine, and combing hair every day. When the wine is used for half month, the problem of losing hair is relieved. Compared with the prior art, the formula for growing hair is mild, suitable for long-term use, low in cost, and free from toxic and side effects. The combination of two using methods of applying and combing is favorable for stimulating hair follicles, activating skin cells, reinforcing blood circulation, promoting hair growth, and achieving a good use effect.
This is a randomized, placebo-controlled, multiple-ascending-dose (MAD) study enrolling subjects with moderately to severely active UC. Subjects with prior exposure to biologic or JAK inhibitors will be limited to 30% of the total subject population; those who have failed 2 or more biologic therapies (i.e., biologic and JAK inhibitor, 2 biologics in the same class, or 2 biologics from different classes) will be limited to 20% of the total subject population. Subjects will be randomized to one of 3 doses of oral BT051 (200 mg, 800 mg, or 3200 mg) or placebo, in ascending dose groups based on the safety and tolerability of the previous cohort. Safety and tolerability will be assessed by a Safety Review Committee (SRC) after all subjects in each cohort have completed at least 14 days of treatment, before proceeding to the next higher dose cohort. The SRC may recommend that the next cohort proceed with a higher dose as planned, or the SRC may recommend additional subjects be dosed at the current, previous, or lower dose of study drug.

Each planned dose escalation cohort (Cohorts 1-3) will include 8 subjects randomized 3:1 to receive active drug or placebo. Starting with the lowest dose, each cohort of subjects will receive once daily oral BT051 or placebo for a period of 28 days. Follow-up visits will be performed at 7 and 30 days after the last dose.
An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk prostate cancers by prostatic implants of androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such prostatic implants renders a constant slow-release of their contents to the prostate for extended periods by biodegradation and diffusion. It facilitates higher prostatic and lower systemic concentrations of androgen suppressive hormones. Because of their high prostatic and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal implant treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of PSA and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage prostate cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage prostate cancer significantly. Androgen suppressive hormonal implants to the prostate before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized prostate cancer as compared to the more complex and toxic higher dose radiation therapy.
The invention belongs to the technical field of biological medicines, and provides application of CALML6 serving as a target in preparation of medicines or reagents for diagnosing or immunotherapy of papillary thyroid cancer in order to solve the problems that existing high-risk subtype Papillary Thyroid Cancer (PTC) lacks effective and accurate distinguishing markers and the like. The application of the CALML6 serving as a target in preparing medicaments or reagents for diagnosing papillary thyroid cancer, the CALML6 is highly expressed in the PTC tissue of the papillary thyroid cancer, and proliferation of PTC cells is promoted. The present invention identifies the diagnostic value of CALML6 for PTC and high cell type PTC. Suggesting that it may be an oncogene for papillary thyroid carcinoma. CALML6 is associated with thyroid immune microenvironment and immune checkpoints. It is likely to be one of the targets for immunotherapy. Further studies on the precise molecular function and expression of CALML6 may provide new targets for diagnosis and treatment of high cell type PTC.
The intervention group will receive real-time gait-training interventions along with a home exercise program. Participants in this group will be given a pair of sensors to wear on their shoes to wear during runs throughout the study period, and wear a Garmin watch to get information from the sensors to the watch for feedback. They will also do home exercises during the study, and to come into the laboratory weekly for about 30 minutes per visit to progress the home exercises and get instructions on feedback for the next week.
Subject is defined as MR if \> 6months of age at diagnosis, OR \< 6 months of age with White Blood cell Count (WBC) \< 300 at diagnosis and good prednisone response. Subject gets 1st cycle of blinatumomab. If MRD is \>0.01%, after 1st cycle of blinatumomab, subject will be allocated to HR treatment from that phase, and will be eligible for HSCT. If MRD is undetectable or \< 0.01% after the 1st cycle of blinatumomab (TP2) patient will be eligible for replacement of MARMA by 2nd cycle of blinatumomab after receipt of lymphoid style consolidation (Protocol IB) or of myeloid style consolidation (ADE/MAE).
A pharmaceutical composition for preventing and treating allergic skin disorder is provided to suppress topical inflammation and inflammatory cytokine using a Houttuynia Cordata Thunb and Ulmus davidana var.Japonica. A pharmaceutical composition for preventing and treating allergic skin disorder comprises a mixed extracts of Houttuynia Cordata Thunb and Ulmus davidana var.Japonica as an active ingredient. The Houttuynia Cordata Thunb is obtained from leaves, stem, root or their mixture of Houttuynia Cordata Thunb. The extract of Houttuynia Cordata Thunb and Ulmus davidana var. Japonica is extracted using hot water, alcohol, or organic solvent. The allergic skin disorder is selected from atopic dermatitis, psoriasis, contact allergic dermatitis and urticaria.
<P>PROBLEM TO BE SOLVED: To provide a medicine useful for the improvement of hypotension after a meal or the prevention of a disease or a state capable of being induced by the hypotension after the meal.  <P>SOLUTION: This improving agent of the hypotension occurring after the meal in a subject having a normal blood sugar value, patient with disease such as neuropathy or heart diseases, etc., elderly person or normal person (e.g. hypotension after the meal) containing an α-glucosidase inhibitor is provided. Also, the preventing agent of the disease or state (e.g. dizziness, faint, myocardial infarction and cerebral infarction) induced by the hypotension after the meal, containing the α-glucosidase inhibitor is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Spinal manipulative therapy will be delivered to the cervical spine (segments including occiput-atlas to C7-D1) according to the chiropractors' evaluation during each visit. During each session, one or two segments will be manipulated using a high-velocity low-amplitude thrust manipulation (a joint cavitation will be expected, if not, the thrust can repeated once) applied to the segments with the highest motion restriction, as determined by the chiropractor by static and motion palpation of the cervical spine.
BACKGROUND: Heterotopic ossification (HO) formation has been increasingly recognized as a complication of major orthopedic surgeries, particularly total hip arthroplasty (THA). Though, the overall incidence of HO following THA has been well-documented, it is often not reported by severity or by surgical approach.
QUESTIONS/PURPOSES: (1) What are the demographics of patients with HO? (2) What is the severity of HO following THA using the Brooker classification? (3) What is the incidence and class of HO following different THA approaches (anterior, posterior, posterolateral, anterolateral, superior, lateral, trans-gluteal)? (4) What are the number and training level of surgeons who performed each procedure?
METHODS: The PubMed, Embase, and Web of Science databases were queried, and PRISMA guidelines were followed. Qualitative and quantitative analyses were performed using Microsoft Excel.
RESULTS: We isolated 26 studies evaluating 6512 total hip arthroplasties (THA). The mean HO percentage overall was 28.8%, mostly Class I (54.2%) or Class II (29.6%). The highest percentage of HO was associated with the modified direct lateral (57.2%) and the traditional lateral (34.6%) approaches. The lowest HO percentages were identified following posterolateral (12.8%) and direct superior approaches (1%). Most studies reported a singular senior surgeon operating within the same approach for all patients.
CONCLUSIONS: The traditional lateral and modified direct lateral approaches to THA resulted in the highest percentage of HO postoperatively. However, most ossification cases were not clinically significant and did not strongly affect overall patient morbidity. Further studies are warranted to identify an association between severity of ossification and different arthroplasty approaches.
To assure safe and effective use of midazolam hydrochloride syrup, the following information and instructions should be communicated to the patient when appropriate:

  1. Inform your physician about any alcohol consumption and medicine you are now taking, especially blood pressure medication, antibiotics, and protease inhibitors, including drugs you buy without a prescription. Alcohol has an increased effect when consumed with benzodiazepines; therefore, caution should be exercised regarding simultaneous ingestion of alcohol during benzodiazepine treatment.
  2. Inform your physician if you are pregnant or are planning to become pregnant.
  3. Inform your physician if you are nursing.
  4. Patients should be informed of the pharmacological effects of midazolam hydrochloride syrup, such as sedation and amnesia, which in some patients may be profound. The decision as to when patients who have received midazolam hydrochloride syrup, particularly on an outpatient basis, may again engage in activities requiring complete mental alertness, operate hazardous machinery or drive a motor vehicle must be individualized.
  5. Midazolam hydrochloride syrup should not be taken in conjunction with grapefruit juice
  6. .For pediatric patients, particular care should be taken to assure safe ambulation.
BACKGROUND AND AIMS: Exclusive enteral nutrition (EEN) with a liquid diet is the only established dietary treatment for Crohn's' disease (CD). However, the mechanism of action of EEN in CD is unclear. T helper 17 (Th17) immune response plays a critical role in CD. We hypothesized that EEN alleviates Th17 response by eliminating mechanical stress-induced expression of Th17-polarizing cytokines.
METHODS: A rat model of Crohn's-like colitis was established by intracolonic instillation of TNBS (65 mg/kg in 250 µL of 40% ethanol). Control rats were treated with saline. We characterized immunophenotypes and molecular changes of the colon in control and colitis rats with and without EEN treatment. Th17 differentiation was determined using coculture assays.
RESULTS: TNBS instillation induced transmural inflammation with stenosis in the inflammation site and a marked increase of Th17-polarizing cytokines interleukin (IL)-6 and osteopontin and the Th17 cell population in the mechanically distended preinflammation site (P-site). EEN treatment eliminated mechanical distention and the increase of IL-6, osteopontin, and Th17 response in the P-site. IL-6 and osteopontin expression was found mainly in the muscularis externa. Mechanical stretch of colonic smooth muscle cells in vitro induced a robust increase of IL-6 and osteopontin. When naïve T cells were cultured with conditioned media from the P-site tissue or stretched cells, Th17 differentiation was significantly increased. Inhibition of IL-6, but not deletion of osteopontin, blocked the increase of Th17 differentiation.
CONCLUSIONS: Mechanical stress induces Th17-polarizing cytokines in the colon. EEN attenuates Th17 immune response by eliminating mechanical stress-induced IL-6 in Crohn's-like colitis.
Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with \< 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADHl, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBsAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAg particles purified from Alexander cells as measured by sucrose gradient sedimentation. The present invention demonstrates synthesis and assembly of a higher ordered multi-component structure resulting from expression of a heterologous DNA coding segment in a microorganism.
Current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. The aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (SRP) and SRP in conjunction with injectable platelet-rich fibrin (i-PRF) application.

Thirty patients with chronic periodontitis who had at least two sites with perriodontal pocket depth (PPD) ≥ 4 mm on contralateral side will be involved in the study. Using a split-mouth design, patients will be treated with SRP + I-PRF -(test group) or SRP only-(control group). Gingival crevicular fluid (GCF) and subgingival plaque will be collected with paper points (DentsplyMaillefer, Tulsa, Oklahoma, USA) at baseline and 1, 3 and 6 months after the treatment. The presence and concentrations of Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi) and Tannerella forsythia(Tf) will be analyzed by real-time polymerase chain reaction (qPCR). Periodontal parameters, including bleeding on probing (BOP), probing pocket depth (PPD) and the clinical attachment level (CAL), will be recorded on both sides, as well as concentration of TNF-alpha (tumor necrosis factor alpha), ALP(alkaline phosphatase) and MMP-8 (matrix-metalloproteinase-8).
Eligible participants will receive a single dose of placebo matching GSK3923868 in Treatment Period 1 followed by a single dose of GSK3923868 1000 mcg in Treatment Period 2. Participants will also receive a repeat dose of GSK3923868 1500 mcg in Treatment Period 3. There will be a washout period between each treatment period. Participants will have a follow-up of 14 days after the last dose of GSK3923868.
The present invention provides one kind of angelica oil extraction process with high yield and high product purity. The technological process adopts methane dichloride as catalyst, includes the steps of distillation, extraction, separation, etc. and has angelica oil yield not lower than 0.45 %. The extracted angelica oil has high purity, refractive index 1.52-1.55 and specific weight of 1.02-1.12. The present invention provides also several angelica oil preparations, including dripping pill, enteric coated dripping pill and coated dripping pill. The process of the present invention is simple, convenient in operation and suitable for industrial production.
Patients receive educational materials and attend a telemedicine visit with a research assistant once a week for 8 weeks while receiving standard of care radiotherapy and prior to standard of care surgery. Patients undergo MRI and CT at week 9.
Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be "semi-standardized," meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content.
Obesity remains a significant global health challenge, with bariatric surgery remaining as one of the most effective treatments for severe obesity and its related comorbidities. This review highlights the multifaceted impact of bariatric surgery beyond mere physical restriction or nutrient malabsorption, underscoring the importance of the gut microbiome and neurohormonal signals in mediating the profound effects on weight loss and behavior modification. The various bariatric surgery procedures, such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), act through distinct mechanisms to alter the gut microbiome, subsequently impacting metabolic health, energy balance, and food reward behaviors. Emerging evidence has shown that bariatric surgery induces profound changes in the composition of the gut microbiome, notably altering the Firmicutes/Bacteroidetes ratio and enhancing populations of beneficial bacteria such as Akkermansia. These microbiota shifts have far-reaching effects beyond gut health, influencing dopamine-mediated reward pathways in the brain and modulating the secretion and action of key gut hormones including ghrelin, leptin, GLP-1, PYY, and CCK. The resultant changes in dopamine signaling and hormone levels contribute to reduced hedonic eating, enhanced satiety, and improved metabolic outcomes. Further, post-bariatric surgical effects on satiation targets are in part mediated by metabolic byproducts of gut microbiota like short-chain fatty acids (SCFAs) and bile acids, which play a pivotal role in modulating metabolism and energy expenditure and reducing obesity-associated inflammation, as well as influencing food reward pathways, potentially contributing to the regulation of body weight and reduction in hedonic eating behaviors. Overall, a better understanding of these mechanisms opens the door to developing non-surgical interventions that replicate the beneficial effects of bariatric surgery on the gut microbiome, dopamine signaling, and gut hormone regulation, offering new avenues for obesity treatment.
PURPOSE:To obtain a soft gel composition having excellent applicability, transparent appearance and moderate fluidity by combining a specific hydrophilic surfactant, an oleophilic surfactant, a polyhydric alcohol, an oil and water. CONSTITUTION:The objective gel cosmetic contains (A) 5-40wt.% of a hydrophilic surfactant (exhibiting liquid or pasty state at room temperature and having an HLB of >=11) selected from polyoxyethylene sorbit fatty acid esters (e.g. sorbit tetrastearate) and polyoxyethylene glycerol fatty acid esters (e.g. glyceryl monooleate), (B) 1-15wt.% of an oleophilic surfactant composed of a mono or diester of glycerol and a branched or unsaturated fatty acid (e.g. diglyceryl monooleate), (C) 1-50wt.% of a polyhydric alcohol (e.g. propylene glycol), (D) 10-90wt.% of a liquid or pasty oil component such as squalane and (E) 1-50wt.% of water. The composition can be used as a cleansing agent, massaging agent, pack cosmetic and pharmaceutical base.